@article{ed8f9aed47d6484bbe7b49a5fb6391e7,
title = "Family-based genome-wide association scan of attention-deficit/ hyperactivity disorder",
abstract = "Objective: Genes likely play a substantial role in the etiology of attention-deficit/hyperactivity disorder (ADHD). However, the genetic architecture of the disorder is unknown, and prior genome-wide association studies (GWAS) have not identified a genome-wide significant association. We have conducted a third, independent, multisite GWAS of DSM-IV-TR ADHD. Method: Families were ascertained at Massachusetts General Hospital (MGH; N = 309 trios), Washington University at St. Louis (WASH-U; N = 272 trios), and University of California at Los Angeles (UCLA; N = 156 trios). Genotyping was conducted with the Illumina Human1M or Human1M-Duo BeadChip platforms. After applying quality control filters, association with ADHD was tested with 835,136 SNPs in 735 DSM-IV ADHD trios from 732 families. Results: Our smallest p value (6.7E-07) did not reach the threshold for genome-wide statistical significance (5.0E-08), but one of the 20 most significant associations was located in a candidate gene of interest for ADHD (SLC9A9, rs9810857, p = 6.4E-6). We also conducted gene-based tests of candidate genes identified in the literature and found additional evidence of association with SLC9A9. Conclusions: We and our colleagues in the Psychiatric GWAS Consortium are working to pool together GWAS samples to establish the large data sets needed to follow-up on these results and to identify genes for ADHD and other disorders.",
keywords = "ADHD, SLC9A9, genome-wide association study",
author = "Eric Mick and Alexandre Todorov and Susan Smalley and Xiaolan Hu and Sandra Loo and Todd, {Richard D.} and Joseph Biederman and Deirdre Byrne and Bryan Dechairo and Allan Guiney and James McCracken and James McGough and Nelson, {Stanley F.} and Reiersen, {Angela M.} and Wilens, {Timothy E.} and Janet Wozniak and Neale, {Benjamin M.} and Faraone, {Stephen V.}",
note = "Funding Information: Genotyping was conducted by Genizon BioSciences Inc. with the financial support of Pfizer Inc. Subject ascertainment and assessment was supported by the following sources: National Institutes of Health (NIH) grants R13MH059126 , R01MH62873 , U01MH085518 and R01MH081803 to S.V.Faraone; National Institute of Neurological Disorders and Stroke (NINDS) grant NS054124 S. Loo; National Institute of Mental Health (NIMH) grant MH01966 to J. McGough; National Institute on Drug Abuse (NIDA) grant K24 DA016264 to T. Wilens; NIMH grant MH63706 to S. Smalley; and NIMH grants K08MH001503 and R01MH066237 to J. Wozniak. Funding Information: Dr. Biederman receives research support from Alza , AstraZeneca , Bristol Myers Squibb , Eli Lilly and Co. , Janssen Pharmaceuticals Inc. , McNeil , Merck , Organon , Otsuka , Shire , the National Institute of Mental Health (NIMH), and the National Institute of Child Health and Human Development (NICHD). He has served on the speakers' bureau for Fundacion Areces, Medice Pharmaceuticals, and the Spanish Child Psychiatry Association. In previous years, Dr. Biederman received research support, consultation fees, or speaker's fees for/from Abbott , AstraZeneca , Celltech , Cephalon , Eli Lilly and Co. , Esai , Forest , Glaxo , Gliatech , Janssen , McNeil , NARSAD , National Institute on Drug Abuse (NIDA), New River , Novartis , Noven , Neurosearch , Pfizer , Pharmacia , The Prechter Foundation , Shire , The Stanley Foundation , UCB Pharma, Inc. , and Wyeth . ",
year = "2010",
month = sep,
doi = "10.1016/j.jaac.2010.02.014",
language = "English",
volume = "49",
pages = "898--905.e3",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
number = "9",
}